rethinkTHC Search
Menu
Study breakdown

Medical cannabis authorization linked to reduced opioid use in high-dose patients

Retrospective CohortStrong evidence
The takeaway

Among chronic opioid users in Alberta, medical cannabis authorization was associated with reduced opioid dosing, particularly in those on the highest doses.

People interested in cannabis as a potential tool for reducing opioid dependence, pain management researchers, and harm reduction advocates.

435.5 mg OME reduction in high-dose opioid patients over 6 months

What the researchers found

Patients on high-dose opioids (OME > 100) who received medical cannabis authorization showed a significant decrease in opioid use of 435.5 mg OME over six months compared to matched controls.

Why it matters

With opioid overdose deaths continuing to climb in North America, any intervention that meaningfully reduces opioid dosing in high-risk patients deserves attention. This population-level data from a Canadian province offers real-world evidence beyond clinical trials.

The numbers in context

5,373 matched pairs; average age 52 years, 54% female; high-dose patients (OME > 100) saw a decrease of 435.5 mg OME (95% CI: -596.8 to -274.2) over 6 months

How the study worked

Researchers propensity-score matched 5,373 medical cannabis-authorized chronic opioid users with non-authorized controls in Alberta from 2013 to 2018. They used interrupted time series analysis to track weekly average oral morphine equivalents 26 weeks before and 52 weeks after authorization.

What this study cannot tell us

Short follow-up period of one year. Cannabis authorization does not confirm actual use. Effects were modest in low-dose opioid users. Observational design limits causal conclusions.

How to read the evidence

Large population-level cohort with propensity-score matching and interrupted time series analysis across a Canadian province.

When this study was published

Published in 2021 using data from 2013-2018.

The bigger picture

This adds to a growing body of evidence suggesting cannabis may function as an opioid-sparing agent, though the effect appears most pronounced in patients already on dangerously high opioid doses.

Questions still open

  • Do these opioid reductions persist beyond one year? What happens to pain management outcomes when opioids are reduced? Which cannabis products or dosing patterns drive the strongest opioid-sparing effect?

Common questions

Did medical cannabis completely replace opioids?
Not in most cases. The study found intermediate effects on opioid use overall, with the most meaningful reductions in patients who started on the highest doses.
How large was this study?
It included 5,373 medical cannabis patients matched to an equal number of controls, all chronic opioid users in Alberta.

Read the original research

Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.

BMC public health, 21(1), 843

Citation

Lee, Cerina; Lin, Mu; Martins, Karen J B; Dyck, Jason R B; Klarenbach, Scott; Richer, Lawrence; Jess, Ed; Hanlon, John G; Hyshka, Elaine; Eurich, Dean T. (2021). Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.. BMC public health, 21(1), 843. https://doi.org/10.1186/s12889-021-10867-w

Explore the wider topic